

SHED LIGHT ON YOUR CELLS

AUTOMATED CELL MONITORING IN REAL-TIME & LABEL-FREE

Ovizio Imaging Systems & Bristol-Myers Squibb

ASGCT - Boston MAY, 14 2020

-0.279 -0.188 -0.098 -0.007 0.084 0.175 0.265 0.356 0.447 0.538 0.628

COMPANY SNAPSHOT



COMPANY FOUNDED IN 2009 BELGIUM - BASED



16 PEOPLE 50% TASK FORCE IN HARDWARE & SOFTWARE



INTELLECTUAL PROPERTY **13 PATENTS FAMILIES**



BIOPROCESSING MARKET



TOP APPLICATIONS:

- CELL & GENE THERAPY
- **RECOMBINANT PROTEINS PRODUCTION**



SPEAKERS



Emilie Viey, PhD. **CEO at Ovizio Imaging Systems** emilie.viey@ovizio.com



Ivie Aifuwa, PhD. Senior Scientist at Bristol-Myers Squibb

ANY LAB FACE BOTTLENECK CHALLENGES WHEN SCALE-UP ACTIVITIES

SAMPLE PREPARATION

2



STAINING

FEED TO OF-LINE

5 READ OUT BY TRAINED OPERATOR





DISPOSAL OF SAMPLE

CELLS IN CULTURE VESSEL

OVIZIO'S VALUE PROPOSITION: BRINGS AUTOMATION IN CELLS EXPANSION

ON-LINE MONITORING & DYE-FREE










OUR CONNEXION IS BIOREACTOR AGNOSTIC


SINGLE-USE & VERSATILE



ASEPTIC CONNECTIONS: WELDING (C-FLEX OR PVC), LUER LOCK CONNECTION OR USING A NOVASEPTUM STERILE CONNECTION.



IMMUNE CELLS FINGERPRINTS: 3D IMAGE-BASED ANALYSIS



PHASE IMAGES (DIFFERENTIAL DIGITAL HOLOGRAPHIC MICROSCOPY)



Automation of T cell Expansion Using the iLine F

May 14, 2020





Highly Confidential

PAT Gaps and Considerations for Cell Therapy

Process Analytical Technology (PAT) consists of "designing, analyzing and controlling manufacturing through timely measurements (i.e., during processing) for critical quality and performance attributes of raw and in-process materials and processes, with the goal of ensuring final product quality"

Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance. (2004)

PAT should provide real-time assessment of :

Critical Process Parameters

- Viable Cell Concentration (VCC)
- Media metabolites/nutrients
- pH/DO

Critical Ouality Attributes

- Cell Phenotype
- Cell Functionality
- Cell Health

Cell Therapy PAT platforms should:

Provide real time monitoring of attributes


Interface with bioreactor/cell therapy processing equipment

Interface directly with control automation

Utilize pre-sterilized, single-use product contact surfaces

Enable non-invasive/non-destructive analysis

Expansion workflow - Manual Expansion




Ovizio iLine F - Online Viable Cell Concentration and Viability



- The iLine F is an **on-line cell counting platform**
 - Dye-free approach to viable cell counting
- BioConnect SUS enables **closed cell processing**, reducing the risk for bioreactor contamination during sampling steps
- Bioreactor agnostic
- With OPC UA and WebServices capabilities, the iLine F can interface with process control systems to enable **automated CAR-T bioreactor operation**

iLine F Operation: Image Acquisition




- Captures 20 images per acquisition per time point
- Captures Z-stacks of each image frame
- OsOne displays the cells within the imaging field of view, as well as process performance attributes

iLine F Operation: Image Analysis - single cell




- Acquired cells undergo image segmentation and analysis
- OsOne then assigns cell viability status and other object classifiers (viable, dead, debris, cluster, etc)
- OsOne displays these classifications in the object/segmentation overlay

iLine F performance strongly fits reference method



- Successfully executed >250 bioreactor expansion runs leveraging iLine F Platform
- iLine F demonstrates good performance within multiple Cell Therapy processes
- iLine F demonstrates good comparability with reference cell counter
- iLine F demonstrated <u>no negative impact to existing Cell Therapy processes</u>


Bind real-time CQAs monitoring (iLine F) & media feeding: increase of growth rate and get higher cell density




- Successfully executed <u>>75 fully automated</u> bioreactor expansion runs leveraging iLine F Platform
 - Shorten the expansion process by 1 day
- Automated expansion may
 - improve cell growth kinetics
 - reduce process variability through timely media feed adjustments

Automated Bioreactor operations

Automated Bioreactor Sampling & Recipe Progression



iLine F for Cell Therapy Expansion







Contact Emilie Viey, PhD CEO emilie.viey@ovizio.com



https://www.linkedin.com/company/ovizioimaging-systems/

www.ovizio.com